The promise of the therapeutic use of cannabidiol for psychiatric disorders

Abstract

Get full access to this article

View all access options for this article.

References

Berger

Rice

, et al. (2022) Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial. Journal of Clinical Psychiatry 83: 21m14130.

Black

Stockings

Campbell

, et al. (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. Lancet Psychiatry 6: 995–1010.

Iffland

Grotenhermen

(2017) An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research 2: 139–154.

Leweke

Piomelli

Pahlisch

, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2: e94.

McGuire

Robson

Cubala

, et al. (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry 175: 225–231.